Clinical Trials
30 trialsNCT05846659 2026-05-15
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT06819735 2026-05-06
DOMISOL
Domain Therapeutics SA
Phase 1/2 Recruiting
NCT06190275 2026-04-24
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
Grit Biotechnology
Phase NA Recruiting
NCT02973789 2026-03-18
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Phase 3 Completed
NCT06710847 2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07171606 2025-12-18
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Recruiting
NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT03792841 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Amgen
Phase 1 Terminated
NCT04631601 2025-10-07
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen
Phase 1/2 Terminated
NCT04417465 2025-09-25
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
AbbVie
Phase 1 Completed
NCT04681131 2025-09-25
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
BioAtla, Inc.
Phase 2 Completed
NCT03425279 2025-09-23
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
BioAtla, Inc.
Phase 1/2 Completed
NCT05509699 2025-08-29
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT06063681 2025-06-08
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Stingray Therapeutics
Phase 1 Recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT04625205 2025-04-06
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
BioNTech SE
Phase 1 Terminated
NCT05497453 2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2 Terminated
NCT03504488 2025-01-15
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
Phase 1/2 Completed
NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
NCT06026254 2024-11-18
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
ImmuneSensor Therapeutics Inc.
Phase 1 Active not recruiting
NCT04673942 2024-10-26
BETA-PRIME
EpicentRx, Inc.
Phase 2 Recruiting
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT05716295 2024-05-08
ORCHID-1
Medikine, Inc.
Phase 1/2 Terminated
NCT04193293 2023-09-21
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
SecuraBio
Phase 1/2 Terminated
NCT03790488 2023-07-03
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
Jounce Therapeutics, Inc.
Phase 1 Completed
NCT05775874 2023-03-20
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Abbisko Therapeutics Co, Ltd
Phase 2 Unknown
NCT05037825 2022-04-27
PARADIGM
VastBiome
Recruiting
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02574533 2017-09-27
Pilot Study of Vigilâ„¢ + Pembrolizumab for Advanced Melanoma
Gradalis, Inc.
Phase 1 Completed